Investigating a new treatment for myelodysplastic syndromes using SX-682 and decitabine.
Official title: A Dose Expansion Study of SX-682 Alone and in Combination with Decitabine in MDS Patients
Funded at Syntrix Biosystems, INC. · NIH-11247621 · Data updated 2026-11-12
This study is looking at a new drug called SX-682 to see how well it works on its own and with another treatment for people with myelodysplastic syndromes (MDS), which can sometimes lead to leukemia, and if you're part of this study, you'll get careful attention and support throughout your treatment.
Quick facts
| Grant type | Sbir 2 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Syntrix Biosystems, INC. NIH-funded |
| Lab location | 1 site (Auburn, United States) |
| Project start | May 1, 2025 |
| Project end | April 30, 2028 |
| Funding year | 2025 |
| Award (this year) | $627,270 |
| NIH project number | 4R44CA291622-02 |
| Project ID | NIH-11247621 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are patients diagnosed with myelodysplastic syndromes who have not responded adequately to existing treatments.
✕Less likely to help
Patients with other types of blood disorders or those who have already received multiple lines of treatment may not benefit from this research.
What this research studies
This research focuses on myelodysplastic syndromes (MDS), which are blood disorders that can lead to acute myeloid leukemia (AML). The study aims to evaluate the effectiveness of a new drug, SX-682, both alone and in combination with decitabine, a currently approved treatment. By targeting specific chemokine receptors that are elevated in patients with MDS, the research seeks to improve treatment outcomes and potentially eradicate the disease-initiating stem cells. Patients participating in this study will receive close monitoring and care as part of the treatment process.
Why it matters
Potential benefit: If successful, this research could provide a more effective treatment option for patients with myelodysplastic syndromes, potentially improving survival rates and quality of life.
How similar studies have gone: While there have been studies on hypomethylating agents for MDS, the specific combination of SX-682 and decitabine represents a novel approach that has not been extensively tested.
Where this research is happening
-
Syntrix Biosystems, INC.
Auburn, United States Active
Researchers
- Principal investigator: Schuler, Aaron D — Syntrix Biosystems, INC.
- Study coordinator: Schuler, Aaron D
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.